Three trials with short-acting GLP-1RAs, exenatide and lixisenatide, showed slowed motor decline, though longer-acting formulations have not replicated this
2022 DOI: 10.1016/S0140-6736(22)02033-5 PMID: 36354040 Read on PubMed The Lancet Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Rosenstock J, Frias J, Jastreboff AM, et al
Thus, these results showed a strong glucose-lowering effects towards a nearly-normal range with weight loss of a not previously reported extent in people with T2DM and without increased risk of clinically significant hypoglycemia [24]
With the increasing prevalence of metabolic diseases globally, interventions targeting GLP-1R could play an important role in reducing the burden of these conditions
The rise of GLP-1 medications like Ozempic, Wegovy, and Mounjaro has sparked a transformative shift in how we approach weight loss
Of course, we have seen weight-loss hype before
